{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:35Z","timestamp":1793386775649,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Brown Physicians Inc","award":["Academic Assessment Grant"],"award-info":[{"award-number":["Academic Assessment Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytomegalovirus (CMV) infection is one of the most common opportunistic infections following organ transplantation, despite administration of CMV prophylaxis. CMV-specific T-cell immunity (TCI) has been associated with reduced rates of CMV infection. We describe for the first\u00a0time clinical experience using the CMV T-Cell Immunity Panel (CMV-TCIP), a commercially available assay which measures CMV-specific CD4+ and CD8+ T-cell responses, to predict clinically significant CMV events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adult (&gt;\u200918-year-old) patients with CMV-TCIP results and\u2009\u2265\u20091 subsequent assessment for CMV DNAemia were included at Brown University and the University of Maryland Medical Center-affiliated hospitals between 4\/2017 and 5\/2019. A clinically significant CMV event was defined as CMV DNAemia prompting initiation of treatment. We excluded indeterminate results, mostly due to background positivity, allogeneic hematopoetic cell transplant (HCT) recipients, or patients who were continued on antiviral therapy against CMV irrespective of the CMV-TCIP result, because ongoing antiviral therapy could prevent a CMV event.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed 44 samples from 37 patients: 31 were solid organ transplant recipients, 4 had hematologic malignancies, 2 had autoimmune disorders. The CMV-protection receiver operating characteristic (ROC) area under the curve (AUC) was significant for %CMV-specific CD4+ (AUC: 0.78, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and borderline for CD8+ (AUC: 0.66, <jats:italic>P<\/jats:italic>\u2009=\u20090.064) T-cells. At a cut-off value of 0.22% CMV-specific CD4+ T-cells, positive predictive value (PPV) for protection against CMV was 85% (95%CI 65\u201396%), and negative predictive value (NPV) was 67% (95%CI 41\u201387%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The CMV-TCIP, in particular %CMV-specific CD4+ T-cells, showed good diagnostic performance to predict CMV events. The CMV-TCIP may be a useful test in clinical practice, and merits further validation in larger prospective studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-020-4787-4","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T14:02:50Z","timestamp":1579269770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinical experience with a novel assay measuring cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity by flow cytometry and intracellular cytokine staining to predict clinically significant CMV events"],"prefix":"10.1186","volume":"20","author":[{"given":"Ralph","family":"Rogers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Saharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Chandorkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe F.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8489-108X","authenticated-orcid":false,"given":"Dimitrios","family":"Farmakiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"4787_CR1","doi-asserted-by":"crossref","unstructured":"Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512.","DOI":"10.1111\/ctr.13512"},{"issue":"6","key":"4787_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900\u201331.","journal-title":"Transplantation."},{"issue":"1","key":"4787_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00277-016-2831-7","volume":"96","author":"K Piukovics","year":"2017","unstructured":"Piukovics K, Terhes G, Gurbity-Palfi T, Bereczki A, Rarosi F, Deak J, et al. Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study. Ann Hematol. 2017;96(1):125\u201331.","journal-title":"Ann Hematol"},{"issue":"15","key":"4787_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1161\/CIRCULATIONAHA.105.607549","volume":"114","author":"W Tu","year":"2006","unstructured":"Tu W, Potena L, Stepick-Biek P, Liu L, Dionis KY, Luikart H, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation. 2006;114(15):1608\u201315.","journal-title":"Circulation"},{"key":"4787_CR5","doi-asserted-by":"crossref","unstructured":"Hecker M, Hecker A, Askevold I, Kuhnert S, Reichert M, Guth S, et al. Indefinite cytomegalovirus prophylaxis with valganciclovir after lung transplantation. Transpl Infect Dis. 2019;21(5):e13138.","DOI":"10.1111\/tid.13138"},{"issue":"9","key":"4787_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/cid\/ciy295","volume":"67","author":"BJ Gardiner","year":"2018","unstructured":"Gardiner BJ, Nierenberg NE, Chow JK, Ruthazer R, Kent DM, Snydman DR. Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2018;67(9):1395\u2013402.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"4787_CR7","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1093\/cid\/cix696","volume":"65","author":"BJ Gardiner","year":"2017","unstructured":"Gardiner BJ, Chow JK, Price LL, Nierenberg NE, Kent DM, Snydman DR. Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2017;65(12):2000\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"4787_CR8","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1111\/ajt.14347","volume":"17","author":"D Kumar","year":"2017","unstructured":"Kumar D, Mian M, Singer L, Humar A. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017;17(9):2468\u201373.","journal-title":"Am J Transplant"},{"issue":"2","key":"4787_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","volume":"9","author":"S Walker","year":"2007","unstructured":"Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, Veale M, et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl Infect Dis. 2007;9(2):165\u201370.","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"4787_CR10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","volume":"9","author":"D Kumar","year":"2009","unstructured":"Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009;9(5):1214\u201322.","journal-title":"Am J Transplant"},{"issue":"6","key":"4787_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/cid\/cis993","volume":"56","author":"O Manuel","year":"2013","unstructured":"Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013;56(6):817\u201324.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4787_CR12","doi-asserted-by":"publisher","first-page":"e01040","DOI":"10.1128\/JCM.01040-17","volume":"56","author":"A Chiereghin","year":"2018","unstructured":"Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, et al. Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection. J Clin Microbiol. 2018;56(4):e01040\u201317.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"4787_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12879-018-3075-z","volume":"18","author":"D Deborska-Materkowska","year":"2018","unstructured":"Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, et al. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients. BMC Infect Dis. 2018;18(1):179.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"4787_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.pathol.2018.04.002","volume":"50","author":"G Thompson","year":"2018","unstructured":"Thompson G, Boan P, Baumwol J, Chakera A, MacQuillan G, Swaminathan S, et al. Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia. Pathology. 2018;50(5):554\u201361.","journal-title":"Pathology"},{"issue":"5","key":"4787_CR15","doi-asserted-by":"publisher","first-page":"e12934","DOI":"10.1111\/tid.12934","volume":"20","author":"S Sood","year":"2018","unstructured":"Sood S, Haifer C, Yu L, Pavlovic J, Gow PJ, Jones RM, et al. Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation. Transpl Infect Dis. 2018;20(5):e12934.","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"4787_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/TP.0000000000002454","volume":"103","author":"GP Westall","year":"2019","unstructured":"Westall GP, Cristiano Y, Levvey BJ, Whitford H, Paraskeva MA, Paul E, et al. A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation. Transplantation. 2019;103(5):1005\u201313.","journal-title":"Transplantation"},{"issue":"6","key":"4787_CR17","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1128\/JCM.06406-11","volume":"50","author":"D Abate","year":"2012","unstructured":"Abate D, Fiscon M, Saldan A, Cofano S, Mengoli C, Sgarabotto D, et al. Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infection. J Clin Microbiol. 2012;50(6):1974\u201380.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"4787_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jcv.2014.09.015","volume":"61","author":"C Costa","year":"2014","unstructured":"Costa C, Balloco C, Sidoti F, Mantovani S, Ritta M, Piceghello A, et al. Evaluation of CMV-specific cellular immune response by EliSPOT assay in kidney transplant patients. J Clin Virol. 2014;61(4):523\u20138.","journal-title":"J Clin Virol"},{"issue":"2","key":"4787_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/tid.12509","volume":"18","author":"F Leone","year":"2016","unstructured":"Leone F, Gigliotti P, Mauro MV, Lofaro D, Greco F, Tenuta R, et al. Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation. Transpl Infect Dis. 2016;18(2):191\u2013201.","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"4787_CR20","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1097\/TP.0000000000001825","volume":"101","author":"T Schachtner","year":"2017","unstructured":"Schachtner T, Stein M, Reinke P. CMV-specific T cell monitoring offers superior risk stratification of CMV-Seronegative kidney transplant recipients of a CMV-seropositive donor. Transplantation. 2017;101(10):e315\u2013e25.","journal-title":"Transplantation"},{"issue":"8","key":"4787_CR21","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.transproceed.2017.07.001","volume":"49","author":"E Favi","year":"2017","unstructured":"Favi E, Santangelo R, Iesari S, Morandi M, Marcovecchio GE, Trecarichi EM, et al. Enzyme-linked immunospot assay as a complementary method to assess and monitor cytomegalovirus infection in kidney transplant recipients on pre-emptive antiviral therapy: a single-center experience. Transplant Proc. 2017;49(8):1766\u201372.","journal-title":"Transplant Proc"},{"key":"4787_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","volume":"105","author":"S Gliga","year":"2018","unstructured":"Gliga S, Korth J, Krawczyk A, Wilde B, Horn PA, Witzke O, et al. T-track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. J Clin Virol. 2018;105:91\u20136.","journal-title":"J Clin Virol"},{"issue":"4","key":"4787_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/tri.13110","volume":"31","author":"B Banas","year":"2018","unstructured":"Banas B, Steubl D, Renders L, Chittka D, Banas MC, Wekerle T, et al. Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. 2018;31(4):436\u201350.","journal-title":"Transpl Int"},{"issue":"3","key":"4787_CR24","doi-asserted-by":"publisher","first-page":"e0193968","DOI":"10.1371\/journal.pone.0193968","volume":"13","author":"D Chanouzas","year":"2018","unstructured":"Chanouzas D, Small A, Borrows R, Ball S. Assessment of the T-SPOT.CMV interferon-gamma release assay in renal transplant recipients: a single center cohort study. PLoS One. 2018;13(3):e0193968.","journal-title":"PLoS One"},{"issue":"11","key":"4787_CR25","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1097\/TP.0000000000002421","volume":"102","author":"M Jarque","year":"2018","unstructured":"Jarque M, Melilli E, Crespo E, Manonelles A, Montero N, Torras J, et al. CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+\/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy. Transplantation. 2018;102(11):e472\u2013e80.","journal-title":"Transplantation"},{"issue":"9","key":"4787_CR26","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/ajt.15315","volume":"19","author":"D Kumar","year":"2019","unstructured":"Kumar D, Chin-Hong P, Kayler L, Wojciechowski D, Limaye AP, Osama Gaber A, et al. A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. Am J Transplant. 2019;19(9):2505\u201316.","journal-title":"Am J Transplant"},{"issue":"Suppl. 1","key":"4787_CR27","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1093\/ofid\/ofx163.1620","volume":"4","author":"CB Lutgen","year":"2017","unstructured":"Lutgen CB, Flebbe-Rehwaldt L, Kleiboeker S, Fausett S, Cordes C, Rodgers J, et al. T-cell immunity panel measures CMV-specific CD4+ and CD8+ responses. Open Forum Infect Dis. 2017;4(Suppl. 1):S615.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"4787_CR28","doi-asserted-by":"publisher","first-page":"ofx143","DOI":"10.1093\/ofid\/ofx143","volume":"4","author":"MV Dioverti","year":"2017","unstructured":"Dioverti MV, Lahr BD, Germer JJ, Yao JD, Gartner ML, Razonable RR. Comparison of standardized cytomegalovirus (CMV) viral load thresholds in whole blood and plasma of solid organ and hematopoietic stem cell transplant recipients with CMV infection and disease. Open Forum Infect Dis. 2017;4(3):ofx143.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"4787_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","volume":"93","author":"LF Lisboa","year":"2012","unstructured":"Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195\u2013200.","journal-title":"Transplantation"},{"issue":"8","key":"4787_CR30","doi-asserted-by":"publisher","first-page":"e106044","DOI":"10.1371\/journal.pone.0106044","volume":"9","author":"E Gabanti","year":"2014","unstructured":"Gabanti E, Bruno F, Lilleri D, Fornara C, Zelini P, Cane I, et al. Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients. PLoS One. 2014;9(8):e106044.","journal-title":"PLoS One"},{"issue":"8","key":"4787_CR31","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1128\/JCM.00563-13","volume":"51","author":"D Abate","year":"2013","unstructured":"Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol. 2013;51(8):2501\u20137.","journal-title":"J Clin Microbiol"},{"issue":"16","key":"4787_CR32","doi-asserted-by":"publisher","first-page":"e15228","DOI":"10.1097\/MD.0000000000015228","volume":"98","author":"Y Ruan","year":"2019","unstructured":"Ruan Y, Guo W, Liang S, Xu Z, Niu T. Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article. Medicine (Baltimore). 2019;98(16):e15228.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"4787_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/CVI.05633-11","volume":"19","author":"MA Clari","year":"2012","unstructured":"Clari MA, Munoz-Cobo B, Solano C, Benet I, Costa E, Remigia MJ, et al. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol. 2012;19(5):791\u20136.","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"4787_CR34","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/00007890-200105150-00018","volume":"71","author":"M Sester","year":"2001","unstructured":"Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation. 2001;71(9):1287\u201394.","journal-title":"Transplantation"},{"issue":"7","key":"4787_CR35","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1084\/jem.20042384","volume":"201","author":"T Bunde","year":"2005","unstructured":"Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201(7):1031\u20136.","journal-title":"J Exp Med"},{"issue":"3","key":"4787_CR36","doi-asserted-by":"publisher","first-page":"381.e1","DOI":"10.1016\/j.cmi.2018.05.010","volume":"25","author":"M Fernandez-Ruiz","year":"2019","unstructured":"Fernandez-Ruiz M, Gimenez E, Vinuesa V, Ruiz-Merlo T, Parra P, Amat P, et al. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 2019;25(3):381.e1\u2013e10.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"4787_CR37","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1128\/JVI.78.11.5535-5545.2004","volume":"78","author":"EJ Wherry","year":"2004","unstructured":"Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol. 2004;78(11):5535\u201345.","journal-title":"J Virol"},{"issue":"6","key":"4787_CR38","doi-asserted-by":"publisher","first-page":"e02128","DOI":"10.1128\/JVI.02128-16","volume":"91","author":"SE Jackson","year":"2017","unstructured":"Jackson SE, Sedikides GX, Mason GM, Okecha G, Wills MR. Human cytomegalovirus (HCMV)-specific CD4(+) T cells are polyfunctional and can respond to HCMV-infected dendritic cells in vitro. J Virol. 2017;91(6):e02128\u201316.","journal-title":"J Virol"},{"issue":"2","key":"4787_CR39","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1128\/JVI.00873-11","volume":"86","author":"R Lachmann","year":"2012","unstructured":"Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A, et al. Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses. J Virol. 2012;86(2):1001\u20139.","journal-title":"J Virol"},{"issue":"2","key":"4787_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/nri3152","volume":"12","author":"SL Swain","year":"2012","unstructured":"Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol. 2012;12(2):136\u201348.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"4787_CR41","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1111\/j.1600-6143.2006.01488.x","volume":"6","author":"G Gerna","year":"2006","unstructured":"Gerna G, Lilleri D, Fornara C, Comolli G, Lozza L, Campana C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant. 2006;6(10):2356\u201364.","journal-title":"Am J Transplant"},{"issue":"12","key":"4787_CR42","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1111\/j.1600-6143.2008.02425.x","volume":"8","author":"G Nebbia","year":"2008","unstructured":"Nebbia G, Mattes FM, Smith C, Hainsworth E, Kopycinski J, Burroughs A, et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant. 2008;8(12):2590\u20139.","journal-title":"Am J Transplant"},{"issue":"10","key":"4787_CR43","doi-asserted-by":"publisher","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","volume":"5","author":"A Meesing","year":"2018","unstructured":"Meesing A, Razonable RR. Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation. Open Forum Infect Dis. 2018;5(10):ofy230.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"4787_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87\u201391.","journal-title":"Clin Infect Dis"},{"key":"4787_CR45","first-page":"941e","volume-title":"Interscience conference on antimicrobial agents and chemotherapy","author":"CJSR Clancy","year":"2011","unstructured":"Clancy CJSR, Hester J, Flebbe-Rehwaldt L, Lutgen C, Yu J, Toyoda Y, Nguyen MH. Prospective study of the kinetics of CMV-specific CD8 and CD4 responses among R+ lung transplant recipients: identifying patients at low risk for active infections off prophylaxis. In: Interscience conference on antimicrobial agents and chemotherapy; 2011. p. 941e."},{"issue":"8","key":"4787_CR46","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1182\/blood-2018-10-878918","volume":"133","author":"JF Camargo","year":"2019","unstructured":"Camargo JF, Wieder ED, Kimble E, Benjamin CL, Kolonias DS, Kwon D, et al. Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood. 2019;133(8):867\u201377.","journal-title":"Blood"},{"issue":"1","key":"4787_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1164\/rccm.201504-0733OC","volume":"193","author":"LD Snyder","year":"2016","unstructured":"Snyder LD, Chan C, Kwon D, Yi JS, Martissa JA, Copeland CA, et al. Polyfunctional T-cell signatures to predict protection from cytomegalovirus after lung transplantation. Am J Respir Crit Care Med. 2016;193(1):78\u201385.","journal-title":"Am J Respir Crit Care Med"}],"updated-by":[{"DOI":"10.1186\/s12879-020-4848-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000}}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4787-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4787-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:06:29Z","timestamp":1610755589000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4787-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4787"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4787-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12879-020-4848-8","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"After publication of the original article [1], we were notified that an author\u2019s family name has been erroneously spelled. Aditya Chandrokar should be replaced with Aditya Chandorkar.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Lifespan and the University of Maryland Medical Center Internal Review Boards, in agreement with the Declaration of Helsinki (Brown IRB study approval # 1346550, UMMC IRB study approval # HP-00082131). A waiver for informed consent was obtained for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DF has received consultant fees and research support by Viracor-Eurofins\u00ae. SK has received research support by Merck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}